Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EUTRON vs DEXEDRINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EUTRON is a combination of hydrochlorothiazide (thiazide diuretic) and pargyline (monoamine oxidase inhibitor, MAOI). Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, reducing plasma volume. Pargyline inhibits MAO, increasing catecholamine levels centrally, leading to antihypertensive effect.
Dextroamphetamine is a central nervous system stimulant that enhances the activity of dopamine and norepinephrine in the brain by blocking their reuptake and increasing their release from presynaptic terminals.
Hypertension
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Oral: 5 mg/2.5 mg (amiodipine/valsartan) once daily; maximum dose 10 mg/320 mg once daily.
5–60 mg/day orally in divided doses, typically 5–20 mg 1–3 times daily; use immediate-release or extended-release formulations per indication.
Terminal elimination half-life is 12-15 hours in patients with normal renal function. In end-stage renal disease (ESRD), half-life may extend to 24-30 hours, requiring dose adjustment.
Terminal elimination half-life is 4-6 hours for dextroamphetamine; clinical effects last longer due to CNS accumulation
Hydrochlorothiazide: primarily excreted unchanged in urine. Pargyline: metabolized via MAO (its target) and other pathways; metabolites excreted renally.
Primarily metabolized by CYP2D6 to 4-hydroxydextroamphetamine, which is further metabolized to various metabolites. Also undergoes deamination and oxidation.
Renal excretion accounts for approximately 90% of elimination, with 70% as unchanged drug and 20% as metabolites. Biliary/fecal excretion accounts for the remaining 10%.
Renal: 30-45% unchanged, 50-60% as deaminated metabolites; fecal: minor (<5%)
Approximately 95% bound to albumin.
Approximately 16-20% bound; primarily to albumin
0.3 L/kg, indicating distribution primarily in extracellular fluid. Higher Vd in heart failure (0.5 L/kg) due to increased tissue perfusion.
3.5-4.5 L/kg; indicates extensive tissue distribution, particularly CNS
Oral: 60-70% due to first-pass metabolism; significantly reduced by food (decrease by 30%).
Oral: 75-100% (immediate-release), 70-90% (extended-release); rectal and parenteral routes are not clinically utilized
e GFR ≥30 m L/min/1.73 m²: No adjustment. e GFR <30 m L/min/1.73 m²: Contraindicated due to valsartan component.
GFR 15–30 m L/min: use with caution, consider dose reduction by 50%. GFR <15 m L/min: not recommended.
Child-Pugh A: No adjustment. Child-Pugh B: Use caution; maximum amiodipine dose 5 mg daily. Child-Pugh C: Not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: not recommended.
Not established for patients <18 years.
Age 3–5 years: 2.5 mg orally once daily, increase by 2.5 mg weekly as needed (max 40 mg/day). Age ≥6 years: 5 mg orally once or twice daily, increase by 5 mg weekly (max 40 mg/day).
Initiate at lowest dose (5 mg/2.5 mg once daily) due to increased sensitivity and reduced hepatic/renal function.
Start at lowest dose (2.5–5 mg orally once daily), titrate slowly; monitor for cardiovascular effects, agitation, and weight loss.
This drug is no longer approved by FDA. Historical black box warning: Pargyline may cause hypertensive crisis when used with certain foods (tyramine-rich) or drugs.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including DEXEDRINE, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
Hypertensive crisis due to dietary tyramine or sympathomimetic drugs,Orthostatic hypotension,Electrolyte imbalance from thiazide,Renal impairment,Hepatic encephalopathy
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems,Blood pressure and heart rate increases,Psychiatric adverse events including exacerbation of pre-existing psychosis, manic episodes, and aggression,Seizures in patients with prior seizure history,Long-term suppression of growth in children,Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome risk when co-administered with serotonergic drugs
Concurrent use of other MAOIs or selective serotonin reuptake inhibitors (SSRIs),Pheochromocytoma,Hypersensitivity to sulfonamides (cross-reactivity with thiazide),Anuria
Known hypersensitivity to amphetamine products or other components of DEXEDRINE,Concurrent use or within 14 days of MAO inhibitor therapy (risk of hypertensive crisis),Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse
Avoid high-tyramine foods (aged cheese, cured meats, fermented foods) due to potential hypertensive crisis with reserpine; avoid excessive sodium intake; maintain adequate potassium intake; limit alcohol.
Avoid high-fat meals with immediate-release formulations as they may delay absorption; for extended-release, high-fat meals can increase peak concentration. Acidic foods (e.g., citrus fruits, fruit juices, carbonated drinks) can reduce absorption. Avoid excessive caffeine (coffee, tea, energy drinks) as it may exacerbate central nervous system stimulation and cardiovascular effects. Maintain adequate hydration. Grapefruit and other CYP2D6 inhibitors may increase effects.
First trimester: Fetal malformations (neural tube defects, cardiovascular anomalies) due to folate antagonism; contraindicated. Second trimester: Increased risk of growth restriction and oligohydramnios. Third trimester: Neonatal adverse effects including bone marrow suppression and pulmonary hypertension.
First trimester: Limited human data; animal studies show increased risk of cardiovascular malformations and cleft palate at high doses. Second/third trimester: Increased risk of preterm delivery, low birth weight, and neonatal withdrawal symptoms (hyperactivity, irritability, feeding difficulties). Dextroamphetamine is a sympathomimetic amine with potential for vasoconstriction reducing uteroplacental perfusion.
Excreted in breast milk; M/P ratio 0.05-0.2. Contraindicated due to risk of neonatal toxicity (myelosuppression, carcinogenesis).
Dextroamphetamine is excreted into breast milk; M/P ratio not established but concentration about 2-7 times maternal plasma. potential for infant stimulation, insomnia, and growth impairment. American Academy of Pediatrics recommends use during breastfeeding only if benefits outweigh risks; monitor infant for agitation and poor weight gain.
Not applicable; contraindicated in pregnancy. No dose adjustment recommended as use is prohibited. If inadvertent exposure occurs, discontinue immediately.
Pharmacokinetic changes in pregnancy: Increased volume of distribution and enhanced renal clearance may reduce serum concentrations of dextroamphetamine. Dose adjustment may be necessary based on clinical response; start with lowest effective dose and monitor for worsening ADHD symptoms. Avoid in severe hypertension or preeclampsia.
EUTRON (combination of hydrochlorothiazide and reserpine) is an older antihypertensive. Reserpine depletes catecholamines, requiring weeks for full effect; may cause depression and nasal congestion. Hydrochlorothiazide increases uric acid; monitor gout and hypokalemia. Discontinue 1-2 weeks before electroconvulsive therapy due to interaction with reserpine.
Monitor for hypertension, tachycardia, and mental status changes (psychosis, mania) especially at high doses. Avoid late-day dosing to prevent insomnia. Use with caution in patients with pre-existing cardiovascular disease or hyperthyroidism. Dextroamphetamine can suppress appetite and cause weight loss; monitor growth in children. Abuse potential is high; schedule II controlled substance. Can precipitate tics in susceptible individuals. Contraindicated within 14 days of MAOIs due to hypertensive crisis.
Take as prescribed; do not stop suddenly as blood pressure may rise.,May cause dizziness or drowsiness; avoid driving if affected.,Report any mood changes, especially depression or suicidal thoughts.,Possible nasal congestion; use saline spray if needed.,Avoid alcohol as it may enhance side effects.,Use sunscreen; may increase sensitivity to sunlight.,May increase blood sugar; monitor if diabetic.,May cause dry mouth; use sugarless gum or candy.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush or chew the extended-release capsules; swallow whole.,Avoid taking the medication in the evening or close to bedtime to prevent trouble sleeping.,Report any chest pain, shortness of breath, fainting, or rapid heart rate to your doctor immediately.,Contact your doctor if you experience new or worsening mental health symptoms such as agitation, aggression, hallucinations, or mania.,You may experience decreased appetite and weight loss; maintain a healthy diet and inform your doctor if weight loss is significant.,Do not stop taking abruptly; taper dose under medical supervision to avoid withdrawal symptoms.,This medication has potential for abuse and dependence; keep in a safe place and do not share with others.,Avoid alcohol and caffeine as they may increase side effects like jitteriness and heart palpitations.,Tell all healthcare providers you are taking this medication, especially before surgery or dental procedures.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EUTRON vs DEXEDRINE, answered by our medical review team.
EUTRON is a Antihypertensive that works by EUTRON is a combination of hydrochlorothiazide (thiazide diuretic) and pargyline (monoamine oxidase inhibitor, MAOI). Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, reducing plasma volume. Pargyline inhibits MAO, increasing catecholamine levels centrally, leading to antihypertensive effect.. DEXEDRINE is a CNS Stimulant that works by Dextroamphetamine is a central nervous system stimulant that enhances the activity of dopamine and norepinephrine in the brain by blocking their reuptake and increasing their release from presynaptic terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EUTRON and DEXEDRINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EUTRON is: Oral: 5 mg/2.5 mg (amiodipine/valsartan) once daily; maximum dose 10 mg/320 mg once daily.. The standard adult dose of DEXEDRINE is: 5–60 mg/day orally in divided doses, typically 5–20 mg 1–3 times daily; use immediate-release or extended-release formulations per indication.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EUTRON and DEXEDRINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EUTRON is classified as Category C. First trimester: Fetal malformations (neural tube defects, cardiovascular anomalies) due to folate antagonism; contraindicated. Second trimester: Increased risk of growth restricti. DEXEDRINE is classified as Category C. First trimester: Limited human data; animal studies show increased risk of cardiovascular malformations and cleft palate at high doses. Second/third trimester: Increased risk of pr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.